Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Company to Host Investor Conference Call Today at 8:30AM EST
PRINCETON, N.J., Dec. 22, 2020 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on develo... Biopharmaceuticals, Oncology Soligenix, dusquetide, oral mucositis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Conferences | Head and Neck Cancer | Marketing | Oral Cancer | Pharmaceuticals